186 related articles for article (PubMed ID: 18199355)
1. Re: Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.
Sherif A
Int Braz J Urol; 2007; 33(6):840-1. PubMed ID: 18199355
[No Abstract] [Full Text] [Related]
2. Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Plasmacytoid Urothelial Bladder Cancer: A Case Report and Review of the Literature.
Gunaratne DA; Krieger LE; Maclean F; Vaux KJ; Chalasani V
Clin Genitourin Cancer; 2016 Feb; 14(1):e103-5. PubMed ID: 26431887
[No Abstract] [Full Text] [Related]
3. Phase II trial of neoadjuvant gemcitabine and cisplatin in patients with resectable bladder carcinoma.
Herchenhorn D; Dienstmann R; Peixoto FA; de Campos FS; Santos VO; Moreira DM; Cardoso H; Small IA; Ferreira CG
Int Braz J Urol; 2007; 33(5):630-8; discussion 638. PubMed ID: 17980060
[TBL] [Abstract][Full Text] [Related]
4. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.
Galsky MD; Pal SK; Chowdhury S; Harshman LC; Crabb SJ; Wong YN; Yu EY; Powles T; Moshier EL; Ladoire S; Hussain SA; Agarwal N; Vaishampayan UN; Recine F; Berthold D; Necchi A; Theodore C; Milowsky MI; Bellmunt J; Rosenberg JE;
Cancer; 2015 Aug; 121(15):2586-93. PubMed ID: 25872978
[TBL] [Abstract][Full Text] [Related]
5. Gemcitabine and cisplatin in locally advanced and/or metastatic bladder cancer.
von der Maase H
Eur J Cancer; 2000 Jul; 36 Suppl 2():13-6. PubMed ID: 10908843
[TBL] [Abstract][Full Text] [Related]
6. Editorial comment on: Long-term survival after gemcitabine and cisplatin in patients with locally advanced transitional cell carcinoma of the bladder: focus on supplementary treatment strategies.
Gschwend JE
Eur Urol; 2007 Aug; 52(2):486-7. PubMed ID: 17383081
[No Abstract] [Full Text] [Related]
7. Neoadjuvant Chemotherapy for Patients with Muscle-invasive Urothelial Bladder Cancer Candidates for Curative Surgery: A Prospective Clinical Trial Based on Cisplatin Feasibility.
Schinzari G; Monterisi S; Pierconti F; Nazzicone G; Marandino L; Orlandi A; Racioppi M; Cassano A; Bassi P; Barone C; Rossi E
Anticancer Res; 2017 Nov; 37(11):6453-6458. PubMed ID: 29061832
[TBL] [Abstract][Full Text] [Related]
8. Expression of nucleoside transporters and deoxycytidine kinase proteins in muscle invasive urothelial carcinoma of the bladder: correlation with pathological response to neoadjuvant platinum/gemcitabine combination chemotherapy.
North S; El-Gehani F; Santos C; Ghosh S; Lai R; Cass CE; Mackey JR
J Urol; 2014 Jan; 191(1):35-9. PubMed ID: 23851183
[TBL] [Abstract][Full Text] [Related]
9. Neoadjuvant chemotherapy with gemcitabine/cisplatin vs. methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: a retrospective analysis from the University of Southern California.
Fairey AS; Daneshmand S; Quinn D; Dorff T; Dorin R; Lieskovsky G; Schuckman A; Cai J; Miranda G; Skinner EC
Urol Oncol; 2013 Nov; 31(8):1737-43. PubMed ID: 23141776
[TBL] [Abstract][Full Text] [Related]
10. Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve.
Gross-Goupil M; Domblides C; Lefort F; Ravaud A
Bull Cancer; 2020 Jun; 107(5S):eS1-eS7. PubMed ID: 32620210
[TBL] [Abstract][Full Text] [Related]
11. Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial.
Pectasides D; Glotsos J; Bountouroglou N; Kouloubinis A; Mitakidis N; Karvounis N; Ziras N; Athanassiou A
Ann Oncol; 2002 Feb; 13(2):243-50. PubMed ID: 11886001
[TBL] [Abstract][Full Text] [Related]
12. Haematological toxicity in patients treated with cisplatin and gemcitabine for bladder cancer: the Weston Park Hospital, Sheffield, experience.
Clenton SJ; Kirkbride P; Ferguson CJ
Clin Oncol (R Coll Radiol); 2006 Oct; 18(8):639. PubMed ID: 17051958
[No Abstract] [Full Text] [Related]
13. The role of taxanes in the management of bladder cancer.
Galsky MD
Oncologist; 2005; 10(10):792-8. PubMed ID: 16314289
[TBL] [Abstract][Full Text] [Related]
14. Gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive transitional and squamous cell carcinoma of the bladder: effect on survival and bladder preservation.
Khaled HM; Shafik HE; Zabhloul MS; Ghoneim M; Saber RA; Manie M; Enein HA; Megeed HA; Mansur O; Sherbini ME; Mahran TZ; Kalawee ME; Badran A; Ramadan SM
Clin Genitourin Cancer; 2014 Oct; 12(5):e233-40. PubMed ID: 24889794
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes following neoadjuvant cisplatin-based chemotherapy for bladder cancer in elderly compared with younger patients.
Chau C; Wheater M; Geldart T; Crabb SJ
Eur J Cancer Care (Engl); 2015 Mar; 24(2):155-62. PubMed ID: 25620269
[TBL] [Abstract][Full Text] [Related]
16. A Phase I Trial of Intravesical Cabazitaxel, Gemcitabine and Cisplatin for the Treatment of Nonmuscle Invasive bacillus Calmette-Guérin Unresponsive or Recurrent/Relapsing Urothelial Carcinoma of the Bladder.
DeCastro GJ; Sui W; Pak JS; Lee SM; Holder D; Kates MM; Virk RK; Drake CG; Anderson CB; James B; Abate-Shen CT; McKiernan JM
J Urol; 2020 Aug; 204(2):247-253. PubMed ID: 32118506
[TBL] [Abstract][Full Text] [Related]
17. Relative efficacy of perioperative gemcitabine and cisplatin versus methotrexate, vinblastine, adriamycin, and cisplatin in the management of locally advanced urothelial carcinoma of the bladder.
Yeshchina O; Badalato GM; Wosnitzer MS; Hruby G; RoyChoudhury A; Benson MC; Petrylak DP; McKiernan JM
Urology; 2012 Feb; 79(2):384-90. PubMed ID: 22196406
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: final results.
Siefker-Radtke AO; Dinney CP; Shen Y; Williams DL; Kamat AM; Grossman HB; Millikan RE
Cancer; 2013 Feb; 119(3):540-7. PubMed ID: 22914978
[TBL] [Abstract][Full Text] [Related]
19. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: a retrospective experience.
Dash A; Pettus JA; Herr HW; Bochner BH; Dalbagni G; Donat SM; Russo P; Boyle MG; Milowsky MI; Bajorin DF
Cancer; 2008 Nov; 113(9):2471-7. PubMed ID: 18823036
[TBL] [Abstract][Full Text] [Related]
20. Phase I Trial of DNA Methyltransferase Inhibitor Guadecitabine Combined with Cisplatin and Gemcitabine for Solid Malignancies Including Urothelial Carcinoma (SPIRE).
Crabb SJ; Danson S; Catto JWF; Hussain S; Chan D; Dunkley D; Downs N; Marwood E; Day L; Saunders G; Light M; Whitehead A; Ellis D; Sarwar N; Enting D; Birtle A; Johnson B; Huddart R; Griffiths G
Clin Cancer Res; 2021 Apr; 27(7):1882-1892. PubMed ID: 33472913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]